Latest news with #CRISPRTherapeuticsAG
Yahoo
21-05-2025
- Business
- Yahoo
CRISPR Therapeutics AG (CRSP) Strikes $95M Deal with Sirius to Develop Blood Clot Drug
CRISPR Therapeutics AG (NASDAQ:CRSP) has entered a $95 million upfront partnership with China-based Sirius Therapeutics to co-develop an siRNA drug targeting blood clotting disorders. This marks a strategic shift for CRISPR, traditionally focused on gene editing, recognizing that siRNA's reversible gene silencing offers advantages for some conditions where permanent DNA edits are risky, such as inhibiting factor XI, a clotting protein, where gene editing could cause bleeding complications. A scientist in a laboratory working on a gene editing tool, to create treatments for rare genetic diseases. Under the deal, CRISPR Therapeutics AG (NASDAQ:CRSP) will pay $25 million upfront plus a $70 million equity investment in Sirius. Both companies will share development costs and profits equally, with CRSP handling U.S. commercialization and Sirius covering Greater China. The siRNA drug, SRSD107, showed promising Phase 1 results by reducing factor XI levels up to 95% and is advancing toward a Phase 3 trial by late 2026. CRISPR Therapeutics AG (NASDAQ:CRSP)'s CEO, Samarth Kulkarni, highlighted the complementary nature of siRNA and gene editing, stating siRNA's quicker regulatory path accelerates commercialization compared to gene editing's longer timeline. The company retains excitement about its CRISPR-based cardiovascular programs, including ANGPTL3 and lipoprotein(a) gene edits, but is open to licensing more siRNA assets from Sirius. This diversified approach aims to build a best-in-class cardiovascular franchise by applying the most appropriate technology for each target. Shortly after, Piper Sandler analyst Raghuram Selvaraju maintained an Overweight rating on CRISPR Therapeutics AG (NASDAQ:CRSP) with a $50 price target, citing the Sirius collaboration as a potential near-term revenue catalyst. While we acknowledge the potential of CRSP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CRSP and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
23-04-2025
- Business
- Yahoo
‘Incoming Regulatory Tailwinds' to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO Capital
Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene therapy product for treating sickle cell disease, Casgevy, faces market hurdles. However, recent political developments, including both at the White House and the Food and Drug Administration (FDA), have paved the way for CRISPR to secure payment for Casgevy and advance new treatments. As a result, I am bullish on CRISPR's prospects in the short term, although some doubts persist in the long term. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. On Wall St., analysts forsee as much as 90% upside over the next twelve months. Earlier today, Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on the stock and has a $97 price target. If accurate, the move would represent a ~156% gain. Biliouris has given his Buy rating due to a combination of factors that highlight Crispr Therapeutics AG's promising growth prospects. Gene therapy is still novel in the U.S. The first gene therapy for cancer was FDA-approved in 2017. Since then, multiple therapies have been approved for various cancers and genetic diseases. Partnered with Vertex Pharmaceuticals (VRTX), CRISPR's Casgevy was one of two gene therapies approved for sickle cell disease in December 2023. After its approval, peak annual revenue estimates for Casgevy were as much as $4 billion, representing a potential windfall for the mid-cap drug developer. However, things have not yet worked as planned. With a price tag of $2.2 million and concerns over long-term side effects (such as the risk of developing secondary leukemia), patients are understandably hesitant to commit to a new, one-and-done gene therapy. In fact, CRISPR has yet to recognize any revenue from Casgevy. Plus, Casgevy's administration is complicated. Authorized treatment centers must be established. Patient cells have to be collected and prepared, which can take up to six months. In the meantime, patients undergo chemotherapy in preparation for Casgevy's administration. CRISPR's last report revealed that 'more than 50 authorized treatment centers have been activated globally (…) and more than 50 patients have already had at least one cell collection.' Notably, CRISPR recognizes revenue only after Casgevy is administered, and, the process can take several months. Also,, consider that CRISPR and Vertex share Casgevy revenues and costs 40/60, respectively. That being said, CRISPR has high hopes for 2025. Moreover, $1.9 billion in the bank and a large partner in Vertex provide some solace during a time of significant net losses ($366 million in 2024). CRISPR has other prospects on which to hang its hat. The company is new to the CAR T-cell therapy scene and is testing its 'next-generation' CAR T-cell therapies for autoimmune diseases and cancers. Notably, several CAR T-cell therapies have been on the market for years, so CRISPR's cell therapies will have to confer benefits over existing ones. In addition to CAR T-cell therapies, CRISPR tests gene therapies for chronic conditions like cardiovascular disease and type 1 diabetes. This is creative given the variety of safe, effective, established, and affordable treatments for these diseases. Luckily for CRISPR and the broader biotechnology sector, recent developments at the FDA, at least for non-vaccine pharmaceutical companies, appear to support novel treatments, especially those aimed at rare diseases. For instance, a new reimbursement model called the Cell and Gene Therapy (CGT) Access Model rolled out at the beginning of the year. Its initial focus is on 'access to gene therapy treatments for people living with sickle cell disease,' making it directly applicable to CRISPR. The proposal calls for increasing Medicaid payment to 75% of gene therapy costs (up from 65%), easing the financial burden on patients. HHS Secretary Robert F. Kennedy Jr., aside from being a former investor of CRSP himself, has expressed support for cell therapies in the past, further signaling an openness to CRISPR's innovative solutions. Lastly, for better or worse, the Trump administration is working to repeal a lot of the regulations that complicate drug development. All in all, the regulatory landscape is looking far brighter for CRSP since Trump and Kennedy Jr. have entered the fray. On Wall Street, CRSP has a Moderate Buy consensus rating based on 12 Buy, six Hold, and one Sell recommendations over the past three months. CRSP's average price target of $71.89 implies a 90% upside potential over the next twelve months. Earlier this month, Needham analyst Gil Blum maintained a Buy rating on CRSP with a price target of $84, noting the company's 'minimal exposure to tariffs' and 'substantial cash reserves' that 'provide a buffer against the high interest rates that are affecting the industry.' The future looks bright for CRISPR stock. All the hard lifting such as establishing treatment centers and securing payer reimbursement to launch Casgevy is now over. As a result, the CGT Access Model is established and will improve patient access to this $2.2 million treatment. It's only a matter of time before CRISPR earns its first revenues from Casgevy, celebrates a major achievement for any drug developer. Still, I have my doubts in the long run. Securing gene therapy approval is just one of many steps. Long-term safety and efficacy outcomes remain necessary to boost adoption, and competitive threats will persist. Moreover, I am not confident in CRISPR's prospects in CAR T-cell therapy, as it is a bit late to the party. Finally, its gene therapies being tested for chronic conditions strikes me as an overly ambitious pursuit. Overall, I am tentatively bullish on CRSP with strong potential upside this year. Disclaimer & DisclosureReport an Issue Sign in to access your portfolio
Yahoo
12-04-2025
- Business
- Yahoo
CRISPR Therapeutics AG (CRSP) Stock Moves -0.03%: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $32.65, marking a -0.03% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 5.98%. Meanwhile, the Dow experienced a drop of 5.5%, and the technology-dominated Nasdaq saw a decrease of 5.82%. Prior to today's trading, shares of the company had lost 24.59% over the past month. This has lagged the Medical sector's loss of 5.46% and the S&P 500's loss of 7.66% in that time. The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. The company's upcoming EPS is projected at -$1.26, signifying a 11.89% increase compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $5.24 million, indicating a 947.2% growth compared to the corresponding quarter of the prior year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$4.99 per share and revenue of $56.98 million. These totals would mark changes of -14.98% and +52.69%, respectively, from last year. Investors should also take note of any recent adjustments to analyst estimates for CRISPR Therapeutics AG. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 2.72% increase. CRISPR Therapeutics AG currently has a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 75, which puts it in the top 31% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
26-03-2025
- Business
- Yahoo
This CRISPR Therapeutics Insider Increased Their Holding In The Last Year
Insiders were net buyers of CRISPR Therapeutics AG's (NASDAQ:CRSP ) stock during the past year. That is, insiders bought more stock than they sold. Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing. Over the last year, we can see that the biggest insider purchase was by Independent Director John Greene for US$314k worth of shares, at about US$44.85 per share. That means that even when the share price was higher than US$40.89 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. The only individual insider to buy over the last year was John Greene. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction! See our latest analysis for CRISPR Therapeutics CRISPR Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying. Over the last three months, we've seen a bit of insider buying at CRISPR Therapeutics. Independent Director John Greene bought US$314k worth of shares in that time. But CEO & Chairman Samarth Kulkarni sold US$281k worth. While it's good to see the insider buying, the net amount bought isn't enough for us to gain much confidence from it. Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. CRISPR Therapeutics insiders own about US$17m worth of shares. That equates to 0.5% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders. Insider purchases may have been minimal, in the last three months, but there was no selling at all. Overall the buying isn't worth writing home about. However, our analysis of transactions over the last year is heartening. Insiders own shares in CRISPR Therapeutics and we see no evidence to suggest they are worried about the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing CRISPR Therapeutics. For example - CRISPR Therapeutics has 1 warning sign we think you should be aware of. Of course CRISPR Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
26-03-2025
- Business
- Yahoo
This CRISPR Therapeutics Insider Increased Their Holding In The Last Year
Insiders were net buyers of CRISPR Therapeutics AG's (NASDAQ:CRSP ) stock during the past year. That is, insiders bought more stock than they sold. Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing. Over the last year, we can see that the biggest insider purchase was by Independent Director John Greene for US$314k worth of shares, at about US$44.85 per share. That means that even when the share price was higher than US$40.89 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. The only individual insider to buy over the last year was John Greene. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction! See our latest analysis for CRISPR Therapeutics CRISPR Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying. Over the last three months, we've seen a bit of insider buying at CRISPR Therapeutics. Independent Director John Greene bought US$314k worth of shares in that time. But CEO & Chairman Samarth Kulkarni sold US$281k worth. While it's good to see the insider buying, the net amount bought isn't enough for us to gain much confidence from it. Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. CRISPR Therapeutics insiders own about US$17m worth of shares. That equates to 0.5% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders. Insider purchases may have been minimal, in the last three months, but there was no selling at all. Overall the buying isn't worth writing home about. However, our analysis of transactions over the last year is heartening. Insiders own shares in CRISPR Therapeutics and we see no evidence to suggest they are worried about the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing CRISPR Therapeutics. For example - CRISPR Therapeutics has 1 warning sign we think you should be aware of. Of course CRISPR Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
